SCM
LCTX icon

Sterling Capital Management’s Lineage Cell Therapeutics LCTX Stock Holding History

Sterling Capital Management’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$848 Buy
+647
New +$894 ﹤0.01% 3158
2025
Q2 		– Sell
-150
Closed -$68 – 3329
2025
Q1 		$68 Hold
150
– – ﹤0.01% 3166
2024
Q4 		$75 Hold
150
– – ﹤0.01% 3192
2024
Q3 		$136 Buy
+150
New +$139 ﹤0.01% 3154

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Sterling Capital Management's LCTX Position: Q2 2026 in Review

Sterling Capital Management opened a new position in Lineage Cell Therapeutics (LCTX) in Q2 2026: 647 shares worth $848. The stake represents ﹤0.01% of the portfolio and ranks #3158 among its holdings. This is a return to the name: Sterling Capital Management previously reported a position in LCTX as recently as Q1 2025.

Sterling Capital Management first reported a position in LCTX in Q3 2024 and has held it in 4 quarters since. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

  • Sterling Capital Management held 647 shares of Lineage Cell Therapeutics worth $848 as of Q2 2026.
  • Lineage Cell Therapeutics was a new Sterling Capital Management position in Q2 2026.
  • Lineage Cell Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #3158 holding.
  • Sterling Capital Management first reported a position in Lineage Cell Therapeutics in Q3 2024 and has held it in 4 quarters since.
  • 132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.